AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Comparison of Single vs. Dual Perclose Devices for Large-Bore Access Closure in TAVR

RecruitingNAAges 18 Years - anyAllWake Forest University Health Sciences
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study will compare the use of one Perclose device to the usual approach of two devices for pre-closure during Transcatheter Aortic Valve Replacement (TAVR). The study will compare the time it takes for bleeding to stop using the different closure approaches. The study will also compare complications when using one Perclose device versus two.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patient age 18 or older * Transfemoral transcatheter aortic valve replacement (TAVR) * Implantation of CoreValve replacement valve * Access using 14 French sheaths * English speaking Exclusion Criteria: * Alternative Access Routes: Patients undergoing transcatheter aortic valve replacement (TAVR) via alternative access routes such as subclavian access or transapical access. * Planned Surgical Cut-Down: Patients planned for surgical cut-down procedures rather than percutaneous access. * Vascular Access Complications: Patients with known vascular complications at the femoral access site, such as residual hematoma, recent femoral arteriotomy or venotomy within the past 10 days, history of significant vascular complications or prior intravascular closure device use within the previous 30 days. * Arterial or Venous Issues: Patients with small femoral arteries or veins (\<5 mm in diameter), patients with access sites located in vascular grafts. * Body Composition: Patients with BMI \>35 * Cardiac Vasculature: Patients with excess calcification of vessels as determined by echocardiography and/or CT angiography * Infection or Inflammation: Active systemic or cutaneous infection or inflammation in the vicinity of the groin. * Coagulation and Hematological Disorders: Known history of bleeding diathesis, coagulopathy, hypercoagulability, or platelet count \<100,000 cells/mmยณ. Pre-existing immunodeficiency disorder or chronic use of high-dose systemic steroids. * Severe Morbidity: Severe co-existing morbidities with a life expectancy less than 12 months. * Mobility Issues: Patients unable to routinely walk at least 20 feet without assistance. * Recent Anticoagulation: Use of low molecular weight heparin (LMWH) within 8 hours before or after the procedure. * Pregnancy and Lactation: Pregnant or lactating women. * Incompatible Procedure Plan: Patients receiving the Edwards Sapien valve (Edwards Lifesciences, Irvine, CA) * Contraindications: Patients with contraindications for the use of Perclose device.
๐Ÿ’Š

What it tests

  • Single Perclose Pro vascular closure device
  • Dual Perclose vascular closure device
๐Ÿ“

Where

1 site
Aurora St. Luke's Medical Center
Milwaukee, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy